Author:
Gennari A,Bruzzi P,Orlandini C,Salvadori B,Donati S,Landucci E,Guarneri V,Rondini M,Ricci S,Conte P
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. A'Hern RP, Smith IE, Ebbs SR (1993) Chemotherapy and survival in advanced breast cancer patients: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67: 801–805
2. Baldini E, Salvadori B, Prochilo Tbolognesi A, Aldrighetti D, Rosso R, Venturini M, Carnino F, Vesentini L, Gallo L, Mammoliti S, Giannesii P, Di Marsico R, Mojano A, Conte PF (2002) Epirubicin (E) followed by paclitaxel (P) vs epirubicin plus paclitaxel (ET) as first line therapy in metastatic breast cancer. Proc Am Soc Clin Oncol 21: 204 (abstr.)
3. Bitran JD, Desser RK, Shapiro CM, Michel A, Kozloff MF, Billings AA, Recent W (1983) Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy. Cancer 51: 381–384
4. Bonneterre J, Mercier M (1993) Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group. Cancer Treat Rev 19(Suppl B): 21–30
5. Buzdar AU, Legha SS, Hortobagyi GN, Yap HY, Wiseman CL, Distefano A, Schell FC, Barnes BC, Campos LT, Blumenschein GR (1981) Management of breast cancer patients failing adjuvant chemotherapy with adriamycin containing regimens. Cancer 47: 2798–2802
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献